If you or a loved one took the drug Dupixent (dupilumab) and were later diagnosed with a rare form of cancer such as cutaneous T-cell lymphoma (CTCL), you may be eligible to file a claim. These lawsuits allege that the manufacturer failed to warn users and healthcare providers about the risk of serious lymphomas linked to Dupixent’s use.
Quick Facts
Category | Detail |
Lawsuit Status | Active — litigation underway against manufacturers |
Product Name | Dupixent (dupilumab) |
Defendant(s) | |
Potential Compensation | Varies depending on injury severity, treatment costs, long-term effects |
Deadline to File | TBD – depends on state statute of limitations |
What is the Dupixent Lawsuit About?
The Dupixent lawsuits focus on allegations that the drug — approved for conditions like moderate to severe eczema, asthma, nasal polyps and other type 2 inflammatory disorders — may be linked to a serious risk of cutaneous T-cell lymphoma (CTCL) and related cancers.
Plaintiffs argue that the manufacturers knew — or should have known — about the potential for these rare lymphomas and failed to provide adequate warnings to patients and healthcare professionals.
In many cases, the concern is that Dupixent may mask, accelerate, or trigger CTCL in patients, especially given that early CTCL symptoms can mimic eczema (one of the conditions Dupixent treats).
Who Qualifies for This Lawsuit?
You may qualify to join the Dupixent lawsuit if:
- You used Dupixent (dupilumab) for a qualifying condition such as eczema, asthma or another approved use
- You were later diagnosed with cutaneous T-cell lymphoma (CTCL) or another related T-cell lymphoma after using the drug
- You have medical records showing use of Dupixent and the diagnosis of CTCL or lymphoma
- You are within your state’s legal filing time window (statute of limitations)
Injuries or Damages Reported
Lawsuits have identified a number of serious complications linked to Dupixent’s use, including:
- Cutaneous T-cell lymphoma (CTCL) — skin-related T-cell cancers including Mycosis Fungoides and Sézary Syndrome.
- Acceleration or worsening of an undiagnosed lymphoma after starting the drug.
- Delayed cancer diagnosis due to initial eczema-like symptoms being treated rather than recognized as lymphoma.
- Medical treatments including chemotherapy, radiation, stem cell transplantation, and long-term monitoring
- Emotional, physical, and economic damages (pain & suffering, lost wages, reduced quality of life)
Dupixent (dupilumab) receives FDA approval for moderate to severe atopic dermatitis (eczema).
Growing case reports and medical studies begin linking use of Dupixent with an increased risk of CTCL.
Attorneys begin filing lawsuits alleging the manufacturers failed to warn about CTCL risks.
Litigation is ongoing; more cases expected and settlement discussions may emerge.
How to File a Claim
Filing a claim is simple and confidential:
- Fill out the short form below
- A participating class action attorney will review your situation
- If you qualify, they’ll file your claim and guide you through the process
You pay nothing upfront — you only pay if compensation is awarded
-
What is the estimated payout for a Dupixent lawsuit?
Settlement amounts vary significantly based on the injury. Ocular (eye) injury cases may range from $100,000 to $400,000, while the newer T-Cell Lymphoma (cancer) claims could see valuations exceeding $500,000 to $1 million+ due to the severity of the diagnosis. Class Action Winning connects you with attorneys who fight to maximize these values.
-
Is there a deadline to file my claim?
Yes. Every state has a strict "Statute of Limitations" (usually 1–3 years from diagnosis). Because the link between Dupixent and Cutaneous T-Cell Lymphoma (CTCL) is a newer discovery, your time to file may be limited. You should submit your details to Class Action Winning immediately to check your specific deadline.
-
Do I have to pay a lawyer upfront to join?
No. These cases are handled on a "contingency fee" basis. You pay $0 upfront. The legal team only gets paid a percentage of the settlement if you win. If you do not receive compensation, you owe nothing.
-
What documents will I need to prove my case?
You will eventually need proof of your Dupixent prescription (pharmacy records) and medical records confirming your diagnosis of severe eye damage (Keratitis) or T-Cell Lymphoma. Don't worry if you don't have these right now; your lawyer can help you gather them.
-
Who are the defendants in this lawsuit?
The lawsuits are filed against Sanofi and Regeneron Pharmaceuticals. Plaintiffs allege these companies aggressively marketed Dupixent while failing to adequately warn patients and doctors about the risks of permanent eye damage and potential malignancies.
-
What specific injuries qualify for a lawsuit?
The primary qualifying injuries are severe ocular conditions (Ulcerative Keratitis, Corneal Perforation, vision loss) and Cutaneous T-Cell Lymphoma (CTCL) (a type of cancer often mistaken for eczema). Mild dry eye or temporary irritation typically does not qualify.
